Identification

Name
Xylometazoline
Accession Number
DB06694
Type
Small Molecule
Groups
Approved, Investigational
Description

A nasal vasoconstricting decongestant drug which acts by binding to the same receptors as adrenaline. It is applied as a spray or as drops into the nose to ease inflammation and congestion of the nasal passageways. It binds alpha-adrenergic receptors to activate the adrenal system which causes systemic vasoconstriction, thereby easing nasal congestion.

Structure
Thumb
Synonyms
  • Balminil
  • Xylomethazoline
Product Ingredients
IngredientUNIICASInChI Key
Xylometazoline hydrochlorideX5S84033NZ1218-35-5YGWFCQYETHJKNX-UHFFFAOYSA-N
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
4 Way Moisturizing ReliefSpray.01 L/LNasalNovartis2010-01-012017-08-19Us
Aqua Maris Fast Acting DecongestantSpray10 mg/10mLNasalJgl North America Llc2012-12-15Not applicableUs
Aqua Maris Kids Fast Acting DecongestantSpray.05 mg/10mLNasalJgl North America Llc2010-09-27Not applicableUs
Balminil DecongestSolution0.1 %NasalTeva2007-12-14Not applicableCanada
Balminil Nasal DecongestantSpray0.1 %NasalTeva1997-08-26Not applicableCanada
Certified Decongestant Nasal Spray .1%Solution; Spray0.1 %NasalProdemdis Enr.1996-09-192010-07-15Canada
Cold & Allergy ReliefSpray0.1 %NasalPharmascience Inc2003-02-01Not applicableCanada
Cold & Allergy Relief With MoisturizersSpray0.1 %NasalPharmascience Inc2003-02-01Not applicableCanada
Cold and Allergy Decongestant Nasal SpraySpray0.1 %NasalTeva2011-10-01Not applicableCanada
Decongest NasalSolution0.1 %NasalTeva2007-12-20Not applicableCanada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Ophtrivin A Ophthalmic DpsXylometazoline hydrochloride (.05 %) + Antazoline sulfate (.5 %)Solution / dropsOphthalmicCiba Vision1992-12-312000-11-08Canada
International/Other Brands
Otriven / Otrivin / Otrivine / Otrix / Xylomet / Xylostar (Intas)
Categories
UNII
WPY40FTH8K
CAS number
526-36-3
Weight
Average: 244.3752
Monoisotopic: 244.193948778
Chemical Formula
C16H24N2
InChI Key
HUCJFAOMUPXHDK-UHFFFAOYSA-N
InChI
InChI=1S/C16H24N2/c1-11-8-13(16(3,4)5)9-12(2)14(11)10-15-17-6-7-18-15/h8-9H,6-7,10H2,1-5H3,(H,17,18)
IUPAC Name
2-[(4-tert-butyl-2,6-dimethylphenyl)methyl]-4,5-dihydro-1H-imidazole
SMILES
CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C

Pharmacology

Indication

It is used for treating nasal congestion and minor inflammation due to allergies or colds.

Associated Conditions
Pharmacodynamics

Xylometazoline is a direct acting sympathomimetic adrenergic alpha-agonist used to induce systemic vasoconstriction, thereby decreasing nasal congestion. The sympathomimetic action of xylometazoline constricts the smaller arterioles of the nasal passages, producing a prolonged (8-12 hours) decongesting effect.

Mechanism of action

Xylometazoline is a direct acting sympathomimetic drug, which acts on alpha-adrenergic receptors in the arterioles of the nasal mucosa. This activates the adrenal system to yield systemic vasoconstrction. In producing vasoconstriction, the result is a decrease in blood flow in the nasal passages and consequently decreased nasal congestion.

TargetActionsOrganism
AAlpha-1A adrenergic receptor
agonist
Human
AAlpha-2A adrenergic receptor
agonist
Human
AAlpha-2B adrenergic receptor
agonist
Human
UAlpha-1B adrenergic receptor
agonist
Human
UAlpha-1D adrenergic receptor
agonist
Human
UAlpha-2C adrenergic receptor
agonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Xylometazoline.Experimental
AcebutololXylometazoline may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved, Investigational
AcemetacinThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcepromazineAcepromazine may decrease the vasoconstricting activities of Xylometazoline.Approved, Vet Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Xylometazoline.Approved, Investigational
AliskirenXylometazoline may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlprenololXylometazoline may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Withdrawn
AmbrisentanXylometazoline may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineXylometazoline may increase the hypotensive activities of Amifostine.Approved, Investigational
AmineptineAmineptine may decrease the antihypertensive activities of Xylometazoline.Illicit, Withdrawn
AmiodaroneXylometazoline may increase the atrioventricular blocking (AV block) activities of Amiodarone.Approved, Investigational
AmitriptylineAmitriptyline may decrease the antihypertensive activities of Xylometazoline.Approved
AmitriptylinoxideAmitriptylinoxide may decrease the antihypertensive activities of Xylometazoline.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Xylometazoline.Approved
AmoxapineAmoxapine may decrease the antihypertensive activities of Xylometazoline.Approved
AmphetamineAmphetamine may increase the hypertensive activities of Xylometazoline.Approved, Illicit, Investigational
AripiprazoleAripiprazole may decrease the vasoconstricting activities of Xylometazoline.Approved, Investigational
ArotinololXylometazoline may increase the atrioventricular blocking (AV block) activities of Arotinolol.Investigational
AsenapineXylometazoline may increase the atrioventricular blocking (AV block) activities of Asenapine.Approved
AtenololXylometazoline may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
AvanafilAvanafil may increase the antihypertensive activities of Xylometazoline.Approved
BarnidipineXylometazoline may increase the antihypertensive activities of Barnidipine.Approved
BefunololXylometazoline may increase the atrioventricular blocking (AV block) activities of Befunolol.Experimental
BenazeprilBenazepril may increase the hypotensive activities of Xylometazoline.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Xylometazoline.Approved
BenmoxinBenmoxin may increase the hypertensive activities of Xylometazoline.Withdrawn
Benzylpenicilloyl PolylysineXylometazoline may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilBepridil may increase the hypotensive activities of Xylometazoline.Approved, Withdrawn
BetaxololXylometazoline may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Xylometazoline.Approved
BevantololXylometazoline may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
BietaserpineBietaserpine may increase the hypotensive activities of Xylometazoline.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Xylometazoline.Approved, Investigational
BisoprololXylometazoline may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
BopindololXylometazoline may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
BosentanBosentan may increase the hypotensive activities of Xylometazoline.Approved, Investigational
BQ-123Xylometazoline may increase the hypotensive activities of BQ-123.Investigational
BretyliumBretylium may increase the hypotensive activities of Xylometazoline.Approved
BrexpiprazoleBrexpiprazole may decrease the vasoconstricting activities of Xylometazoline.Approved, Investigational
BrimonidineBrimonidine may increase the antihypertensive activities of Xylometazoline.Approved
BrofaromineBrofaromine may increase the hypertensive activities of Xylometazoline.Experimental
BromocriptineBromocriptine may increase the hypertensive and vasoconstricting activities of Xylometazoline.Approved, Investigational
BucindololXylometazoline may increase the atrioventricular blocking (AV block) activities of Bucindolol.Investigational
BufuralolXylometazoline may increase the atrioventricular blocking (AV block) activities of Bufuralol.Experimental, Investigational
BunazosinBunazosin may decrease the vasoconstricting activities of Xylometazoline.Investigational
BupranololXylometazoline may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
ButriptylineButriptyline may decrease the antihypertensive activities of Xylometazoline.Approved
CabergolineCabergoline may increase the hypertensive and vasoconstricting activities of Xylometazoline.Approved
CadralazineCadralazine may increase the hypotensive activities of Xylometazoline.Experimental
CafedrineXylometazoline may increase the hypotensive activities of Cafedrine.Investigational
CandesartanXylometazoline may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilCandesartan cilexetil may increase the hypotensive activities of Xylometazoline.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Xylometazoline.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Xylometazoline.Approved
CaroxazoneCaroxazone may increase the hypertensive activities of Xylometazoline.Withdrawn
CarteololXylometazoline may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved
CarvedilolXylometazoline may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Investigational
CeliprololXylometazoline may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved, Investigational
ChlorothiazideChlorothiazide may increase the hypotensive activities of Xylometazoline.Approved, Vet Approved
ChlorpromazineChlorpromazine may decrease the vasoconstricting activities of Xylometazoline.Approved, Investigational, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Xylometazoline.Approved
CicletanineXylometazoline may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilCilazapril may increase the hypotensive activities of Xylometazoline.Approved
ClomipramineClomipramine may decrease the antihypertensive activities of Xylometazoline.Approved, Investigational, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Xylometazoline.Approved
CloranololXylometazoline may increase the atrioventricular blocking (AV block) activities of Cloranolol.Experimental
ClozapineClozapine may decrease the vasoconstricting activities of Xylometazoline.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Xylometazoline.Approved
CyclopenthiazideXylometazoline may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideCyclothiazide may increase the hypotensive activities of Xylometazoline.Approved
DapiprazoleDapiprazole may decrease the vasoconstricting activities of Xylometazoline.Approved
DebrisoquinDebrisoquin may increase the hypotensive activities of Xylometazoline.Approved, Investigational
DelaprilXylometazoline may increase the hypotensive activities of Delapril.Experimental
DeserpidineXylometazoline may increase the hypotensive activities of Deserpidine.Approved
DesipramineDesipramine may decrease the antihypertensive activities of Xylometazoline.Approved, Investigational
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Xylometazoline.Approved, Investigational
DextroamphetamineDextroamphetamine may decrease the vasoconstricting activities of Xylometazoline.Approved, Illicit
DiazoxideDiazoxide may increase the hypotensive activities of Xylometazoline.Approved
DibenzepinDibenzepin may decrease the antihypertensive activities of Xylometazoline.Experimental
DiethylnorspermineDiethylnorspermine may increase the hypotensive activities of Xylometazoline.Investigational
DihydralazineDihydralazine may increase the hypotensive activities of Xylometazoline.Approved, Investigational
DihydroergocornineDihydroergocornine may increase the hypertensive activities of Xylometazoline.Approved
DihydroergocristineDihydroergocristine may increase the hypertensive activities of Xylometazoline.Approved, Experimental
DihydroergocryptineDihydroergocryptine may increase the hypertensive activities of Xylometazoline.Experimental
DihydroergotamineDihydroergotamine may increase the hypertensive and vasoconstricting activities of Xylometazoline.Approved, Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Xylometazoline.Approved, Investigational
DimetacrineDimetacrine may decrease the antihypertensive activities of Xylometazoline.Approved, Withdrawn
DipyridamoleDipyridamole may increase the antihypertensive activities of Xylometazoline.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Xylometazoline.Approved
DosulepinDosulepin may decrease the antihypertensive activities of Xylometazoline.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Xylometazoline.Approved
DoxepinDoxepin may decrease the antihypertensive activities of Xylometazoline.Approved, Investigational
DronedaroneDronedarone may decrease the vasoconstricting activities of Xylometazoline.Approved
DroperidolDroperidol may decrease the vasoconstricting activities of Xylometazoline.Approved, Vet Approved
DuloxetineDuloxetine may increase the tachycardic activities of Xylometazoline.Approved
EfonidipineXylometazoline may increase the hypotensive activities of Efonidipine.Approved, Investigational
EnalaprilEnalapril may increase the hypotensive activities of Xylometazoline.Approved, Vet Approved
EnalaprilatXylometazoline may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Xylometazoline.Experimental
EpanololXylometazoline may increase the atrioventricular blocking (AV block) activities of Epanolol.Experimental
EpinephrineEpinephrine may decrease the vasoconstricting activities of Xylometazoline.Approved, Vet Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Xylometazoline.Approved
EprosartanEprosartan may increase the hypotensive activities of Xylometazoline.Approved
Ergoloid mesylateErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Xylometazoline.Approved
ErgonovineErgonovine may increase the hypertensive and vasoconstricting activities of Xylometazoline.Approved
ErgotamineErgotamine may increase the hypertensive and vasoconstricting activities of Xylometazoline.Approved
EsatenololXylometazoline may increase the atrioventricular blocking (AV block) activities of Esatenolol.Experimental
EscitalopramEscitalopram may decrease the vasoconstricting activities of Xylometazoline.Approved, Investigational
EsmololXylometazoline may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
FelodipineFelodipine may increase the hypotensive activities of Xylometazoline.Approved, Investigational
FenoldopamFenoldopam may increase the hypotensive activities of Xylometazoline.Approved
FentanylThe serum concentration of Fentanyl can be decreased when it is combined with Xylometazoline.Approved, Illicit, Investigational, Vet Approved
Ferulic acidXylometazoline may increase the hypotensive activities of Ferulic acid.Experimental
FlupentixolFlupentixol may decrease the vasoconstricting activities of Xylometazoline.Approved, Investigational, Withdrawn
FosinoprilFosinopril may increase the hypotensive activities of Xylometazoline.Approved
FostamatinibFostamatinib may increase the antihypertensive activities of Xylometazoline.Approved, Investigational
FurazolidoneFurazolidone may increase the hypertensive activities of Xylometazoline.Approved, Investigational, Vet Approved
GuanabenzGuanabenz may increase the hypotensive activities of Xylometazoline.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Xylometazoline.Approved
GuanazodineXylometazoline may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Xylometazoline.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Xylometazoline.Approved, Investigational
GuanoclorXylometazoline may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzXylometazoline may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanXylometazoline may increase the hypotensive activities of Guanoxan.Experimental
HarmalineHarmaline may increase the hypertensive activities of Xylometazoline.Experimental
HexamethoniumXylometazoline may increase the hypotensive activities of Hexamethonium.Experimental
HyaluronidaseHyaluronidase may increase the vasoconstricting activities of Xylometazoline.Approved, Investigational
HydracarbazineHydracarbazine may increase the hypertensive activities of Xylometazoline.Experimental
HydralazineHydralazine may increase the hypotensive activities of Xylometazoline.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Xylometazoline.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Xylometazoline.Approved, Investigational
IloperidoneIloperidone may decrease the vasoconstricting activities of Xylometazoline.Approved
IloprostIloprost may increase the hypotensive activities of Xylometazoline.Approved, Investigational
ImidaprilXylometazoline may increase the hypotensive activities of Imidapril.Investigational
ImipramineImipramine may decrease the antihypertensive activities of Xylometazoline.Approved
IndapamideIndapamide may increase the hypotensive activities of Xylometazoline.Approved
IndenololXylometazoline may increase the atrioventricular blocking (AV block) activities of Indenolol.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Xylometazoline.Withdrawn
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Xylometazoline.Approved, Investigational
IprindoleIprindole may decrease the antihypertensive activities of Xylometazoline.Experimental
IproclozideIproclozide may increase the hypertensive activities of Xylometazoline.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of Xylometazoline.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Xylometazoline.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Xylometazoline.Approved
IsradipineIsradipine may increase the hypotensive activities of Xylometazoline.Approved, Investigational
KetanserinKetanserin may increase the hypotensive activities of Xylometazoline.Investigational
LabetalolXylometazoline may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved
LacidipineXylometazoline may increase the hypotensive activities of Lacidipine.Approved, Investigational
LandiololXylometazoline may increase the atrioventricular blocking (AV block) activities of Landiolol.Investigational
LatanoprostLatanoprost may increase the hypotensive activities of Xylometazoline.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Xylometazoline.Approved, Investigational
LevobetaxololXylometazoline may increase the atrioventricular blocking (AV block) activities of Levobetaxolol.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Xylometazoline.Approved, Investigational
LinsidomineXylometazoline may increase the hypotensive activities of Linsidomine.Experimental
LisdexamfetamineLisdexamfetamine may decrease the vasoconstricting activities of Xylometazoline.Approved, Investigational
LisinoprilLisinopril may increase the hypotensive activities of Xylometazoline.Approved, Investigational
LisurideLisuride may increase the hypertensive activities of Xylometazoline.Approved, Investigational
LofepramineLofepramine may decrease the antihypertensive activities of Xylometazoline.Experimental
LofexidineLofexidine may increase the hypotensive activities of Xylometazoline.Approved, Investigational
LosartanLosartan may increase the hypotensive activities of Xylometazoline.Approved
Lysergic Acid DiethylamideLysergic Acid Diethylamide may increase the hypertensive activities of Xylometazoline.Illicit, Investigational, Withdrawn
MacitentanXylometazoline may increase the hypotensive activities of Macitentan.Approved
ManidipineXylometazoline may increase the hypotensive activities of Manidipine.Approved, Investigational
MebanazineMebanazine may increase the hypertensive activities of Xylometazoline.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Xylometazoline.Approved, Investigational
MelitracenMelitracen may decrease the antihypertensive activities of Xylometazoline.Experimental, Investigational
MepindololXylometazoline may increase the atrioventricular blocking (AV block) activities of Mepindolol.Experimental
MetergolineMetergoline may increase the hypertensive activities of Xylometazoline.Experimental
MethoserpidineXylometazoline may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineMethotrimeprazine may decrease the vasoconstricting activities of Xylometazoline.Approved, Investigational
MethyldopaMethyldopa may increase the hypotensive activities of Xylometazoline.Approved
Methylene blueMethylene blue may increase the hypertensive activities of Xylometazoline.Approved, Investigational
MethylergometrineMethylergometrine may increase the hypertensive and vasoconstricting activities of Xylometazoline.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Xylometazoline.Approved, Investigational
MethysergideMethysergide may increase the hypertensive activities of Xylometazoline.Approved
MetipranololMetipranolol may increase the hypotensive activities of Xylometazoline.Approved
MetolazoneMetolazone may increase the hypotensive activities of Xylometazoline.Approved
MetoprololXylometazoline may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved, Investigational
MetyrosineXylometazoline may increase the hypotensive activities of Metyrosine.Approved
MianserinThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Mianserin.Approved, Investigational
MibefradilMibefradil may increase the hypotensive activities of Xylometazoline.Investigational, Withdrawn
MilnacipranMilnacipran may increase the tachycardic activities of Xylometazoline.Approved, Investigational
MinaprineMinaprine may increase the hypertensive activities of Xylometazoline.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Xylometazoline.Approved, Investigational
MirodenafilMirodenafil may increase the antihypertensive activities of Xylometazoline.Investigational
MirtazapineMirtazapine may decrease the antihypertensive activities of Xylometazoline.Approved
MoclobemideMoclobemide may increase the hypertensive activities of Xylometazoline.Approved, Investigational
MoexiprilMoexipril may increase the hypotensive activities of Xylometazoline.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Xylometazoline.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Xylometazoline.Approved, Investigational
MuzolimineXylometazoline may increase the hypotensive activities of Muzolimine.Experimental
NadololXylometazoline may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
NaftopidilXylometazoline may increase the hypotensive activities of Naftopidil.Investigational
NebivololXylometazoline may increase the atrioventricular blocking (AV block) activities of Nebivolol.Approved, Investigational
NefazodoneNefazodone may decrease the vasoconstricting activities of Xylometazoline.Approved, Withdrawn
NialamideNialamide may increase the hypertensive activities of Xylometazoline.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Xylometazoline.Approved, Investigational
NicergolineNicergoline may increase the hypertensive activities of Xylometazoline.Approved, Investigational
NicorandilXylometazoline may increase the hypotensive activities of Nicorandil.Approved, Investigational
NiguldipineXylometazoline may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineXylometazoline may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimodipineNimodipine may increase the hypotensive activities of Xylometazoline.Approved, Investigational
NisoldipineNisoldipine may increase the hypotensive activities of Xylometazoline.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Xylometazoline.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Xylometazoline.Approved, Investigational
NortriptylineNortriptyline may decrease the antihypertensive activities of Xylometazoline.Approved
ObinutuzumabXylometazoline may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypertensive activities of Xylometazoline.Withdrawn
OlanzapineOlanzapine may decrease the vasoconstricting activities of Xylometazoline.Approved, Investigational
OlmesartanOlmesartan may increase the hypotensive activities of Xylometazoline.Approved, Investigational
OmapatrilatOmapatrilat may increase the hypotensive activities of Xylometazoline.Investigational
OpipramolOpipramol may decrease the antihypertensive activities of Xylometazoline.Investigational
OxprenololXylometazoline may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved
PaliperidonePaliperidone may decrease the vasoconstricting activities of Xylometazoline.Approved
PargylinePargyline may increase the hypertensive activities of Xylometazoline.Approved
Patent BlueThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Patent Blue.Approved
PenbutololXylometazoline may increase the atrioventricular blocking (AV block) activities of Penbutolol.Approved, Investigational
PentoliniumPentolinium may increase the hypotensive activities of Xylometazoline.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Xylometazoline.Approved, Investigational
PergolidePergolide may increase the hypertensive activities of Xylometazoline.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilPerindopril may increase the hypotensive activities of Xylometazoline.Approved
PhenelzinePhenelzine may increase the hypertensive activities of Xylometazoline.Approved
PheniprazinePheniprazine may increase the hypertensive activities of Xylometazoline.Withdrawn
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Xylometazoline.Approved
PhenoxypropazinePhenoxypropazine may increase the hypertensive activities of Xylometazoline.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Xylometazoline.Approved
PinacidilPinacidil may increase the hypotensive activities of Xylometazoline.Approved
PindololXylometazoline may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved, Investigational
PirlindolePirlindole may increase the hypertensive activities of Xylometazoline.Approved
PivhydrazinePivhydrazine may increase the hypertensive activities of Xylometazoline.Withdrawn
PizotifenPizotifen may decrease the vasoconstricting activities of Xylometazoline.Approved
Platelet Activating FactorXylometazoline may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Experimental
PolythiazidePolythiazide may increase the hypotensive activities of Xylometazoline.Approved
PractololXylometazoline may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
PrazosinPrazosin may increase the hypotensive activities of Xylometazoline.Approved
ProcaineProcaine may increase the hypertensive activities of Xylometazoline.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the hypertensive activities of Xylometazoline.Approved, Investigational
PromazinePromazine may decrease the vasoconstricting activities of Xylometazoline.Approved, Vet Approved
PropafenoneXylometazoline may increase the atrioventricular blocking (AV block) activities of Propafenone.Approved
PropericiazinePropericiazine may decrease the vasoconstricting activities of Xylometazoline.Approved, Investigational
PropiomazinePropiomazine may decrease the vasoconstricting activities of Xylometazoline.Approved
PropiverinePropiverine may decrease the vasoconstricting activities of Xylometazoline.Approved, Investigational
PropranololXylometazoline may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Investigational
ProtriptylineProtriptyline may decrease the antihypertensive activities of Xylometazoline.Approved
QuetiapineQuetiapine may decrease the vasoconstricting activities of Xylometazoline.Approved
QuinaprilQuinapril may increase the hypotensive activities of Xylometazoline.Approved, Investigational
QuinidineQuinidine may decrease the vasoconstricting activities of Xylometazoline.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Xylometazoline.Approved
RacepinephrineRacepinephrine may decrease the vasoconstricting activities of Xylometazoline.Approved
RamiprilRamipril may increase the hypotensive activities of Xylometazoline.Approved
RasagilineRasagiline may increase the hypertensive activities of Xylometazoline.Approved
RemikirenRemikiren may increase the hypotensive activities of Xylometazoline.Approved
RescinnamineXylometazoline may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Xylometazoline.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Xylometazoline.Approved, Investigational
RiociguatXylometazoline may increase the hypotensive activities of Riociguat.Approved
RisperidoneRisperidone may decrease the vasoconstricting activities of Xylometazoline.Approved, Investigational
RituximabXylometazoline may increase the hypotensive activities of Rituximab.Approved
SafrazineSafrazine may increase the hypertensive activities of Xylometazoline.Withdrawn
SaprisartanSaprisartan may increase the hypotensive activities of Xylometazoline.Experimental
SelegilineSelegiline may increase the hypertensive activities of Xylometazoline.Approved, Investigational, Vet Approved
SelexipagXylometazoline may increase the hypotensive activities of Selexipag.Approved
SildenafilSildenafil may increase the antihypertensive activities of Xylometazoline.Approved, Investigational
SilodosinSilodosin may decrease the vasoconstricting activities of Xylometazoline.Approved
SitaxentanXylometazoline may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SotalolXylometazoline may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
SpiraprilSpirapril may increase the hypotensive activities of Xylometazoline.Approved
SpironolactoneSpironolactone may decrease the vasoconstricting activities of Xylometazoline.Approved
TadalafilTadalafil may increase the antihypertensive activities of Xylometazoline.Approved, Investigational
TalinololXylometazoline may increase the atrioventricular blocking (AV block) activities of Talinolol.Investigational
TamsulosinTamsulosin may decrease the vasoconstricting activities of Xylometazoline.Approved, Investigational
TelmisartanTelmisartan may increase the hypotensive activities of Xylometazoline.Approved, Investigational
TemocaprilXylometazoline may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerazosinTerazosin may decrease the vasoconstricting activities of Xylometazoline.Approved
TerbutalineXylometazoline may increase the atrioventricular blocking (AV block) activities of Terbutaline.Approved
TergurideTerguride may increase the hypertensive activities of Xylometazoline.Experimental
TerlipressinTerlipressin may increase the hypotensive activities of Xylometazoline.Approved, Investigational
TertatololXylometazoline may increase the atrioventricular blocking (AV block) activities of Tertatolol.Experimental
TetrahydropalmatineXylometazoline may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TheodrenalineXylometazoline may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineTheophylline may increase the antihypertensive activities of Xylometazoline.Approved
ThioproperazineThioproperazine may decrease the vasoconstricting activities of Xylometazoline.Approved
ThioridazineThioridazine may decrease the vasoconstricting activities of Xylometazoline.Approved, Withdrawn
TianeptineTianeptine may decrease the antihypertensive activities of Xylometazoline.Approved, Investigational
TiboloneXylometazoline may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenTicrynafen may increase the hypotensive activities of Xylometazoline.Withdrawn
TimololXylometazoline may increase the atrioventricular blocking (AV block) activities of Timolol.Approved
TolazolineTolazoline may increase the hypotensive activities of Xylometazoline.Approved, Vet Approved
TolonidineXylometazoline may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypertensive activities of Xylometazoline.Approved
TorasemideTorasemide may increase the hypotensive activities of Xylometazoline.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Xylometazoline.Approved
TranylcypromineTranylcypromine may increase the hypertensive activities of Xylometazoline.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Xylometazoline.Approved
TrazodoneTrazodone may decrease the vasoconstricting activities of Xylometazoline.Approved, Investigational
TreprostinilTreprostinil may increase the hypotensive activities of Xylometazoline.Approved, Investigational
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Xylometazoline.Approved, Vet Approved
TrifluoperazineTrifluoperazine may decrease the vasoconstricting activities of Xylometazoline.Approved, Investigational
TrimazosinTrimazosin may increase the hypotensive activities of Xylometazoline.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Xylometazoline.Approved, Investigational
TrimipramineTrimipramine may decrease the antihypertensive activities of Xylometazoline.Approved
UdenafilUdenafil may increase the antihypertensive activities of Xylometazoline.Approved, Investigational
UnoprostoneXylometazoline may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of Xylometazoline.Investigational
ValsartanValsartan may increase the hypotensive activities of Xylometazoline.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Xylometazoline.Approved
VenlafaxineVenlafaxine may increase the tachycardic activities of Xylometazoline.Approved
VerapamilVerapamil may decrease the vasoconstricting activities of Xylometazoline.Approved
VincamineXylometazoline may increase the hypotensive activities of Vincamine.Experimental
VinpocetineXylometazoline may increase the hypotensive activities of Vinpocetine.Investigational
XipamideXylometazoline may increase the hypotensive activities of Xipamide.Experimental
YohimbineYohimbine may decrease the antihypertensive activities of Xylometazoline.Approved, Investigational, Vet Approved
ZiprasidoneZiprasidone may decrease the vasoconstricting activities of Xylometazoline.Approved
ZofenoprilXylometazoline may increase the hypotensive activities of Zofenopril.Experimental
ZuclopenthixolZuclopenthixol may decrease the vasoconstricting activities of Xylometazoline.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi: 10.1111/j.1472-8206.2009.00805.x. [PubMed:20030735]
External Links
Human Metabolome Database
HMDB0015640
KEGG Compound
C07913
PubChem Compound
5709
PubChem Substance
99443248
ChemSpider
5507
BindingDB
30703
ChEBI
10082
ChEMBL
CHEMBL312448
PharmGKB
PA165958368
IUPHAR
517
Guide to Pharmacology
GtP Drug Page
Wikipedia
Xylometazoline
ATC Codes
S01GA53 — Xylometazoline, combinationsR01AB06 — XylometazolineR01AA07 — XylometazolineS01GA03 — Xylometazoline
AHFS Codes
  • 04:00.00 — Antihistamine Drugs
  • 52:32.00 — Vasoconstrictors

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentAcute Rhinitis1
4CompletedTreatmentFlexible Nasendoscopy1
4CompletedTreatmentObstructive Sleep Apnea Syndrome (OSAS) / Rhinitis1
Not AvailableCompletedNot AvailableAcute Rhinitis1
Not AvailableCompletedTreatmentBronchiolitis1
Not AvailableNot Yet RecruitingHealth Services ResearchBronchoscopy1
Not AvailableRecruitingDiagnosticNasal Obstruction / Obstructive Sleep Apnea (OSA)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
SprayNasal.01 L/L
SprayNasal10 mg/10mL
SprayNasal.05 mg/10mL
SolutionNasal0.1 %
SprayNasal0.1 %
Solution; sprayNasal0.1 %
Solution; sprayNasal.1 %
SprayNasal.1 %
Solution / dropsNasal0.1 %
Solution / dropsOphthalmic
SprayNasal0.05 %
Solution / dropsNasal0.05 %
Liquid; sprayNasal.1 %
Solution / dropsNasal.05 %
SprayNasal.05 %
SprayNasal.015 mL/15mL
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)132 °CPhysProp
logP3.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00893 mg/mLALOGPS
logP4.68ALOGPS
logP3.78ChemAxon
logS-4.4ALOGPS
pKa (Strongest Basic)10.29ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area24.39 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity77.82 m3·mol-1ChemAxon
Polarizability29.85 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9866
Blood Brain Barrier+0.7293
Caco-2 permeable-0.5133
P-glycoprotein substrateSubstrate0.8254
P-glycoprotein inhibitor INon-inhibitor0.7469
P-glycoprotein inhibitor IINon-inhibitor0.8244
Renal organic cation transporterInhibitor0.6924
CYP450 2C9 substrateNon-substrate0.7815
CYP450 2D6 substrateNon-substrate0.531
CYP450 3A4 substrateNon-substrate0.5755
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9031
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9147
Ames testNon AMES toxic0.8306
CarcinogenicityNon-carcinogens0.9124
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.1884 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9218
hERG inhibition (predictor II)Non-inhibitor0.745
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-0090000000-c862fcdd09df2d7e84e1
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-0090000000-8a168e444e92aebe729e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-0190000000-fea379e1a78158c80c57
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-0490000000-f84be52191db834c336a
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-01s2-1950000000-6ff7d495e9ab66e5291e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-01ta-1920000000-4fa30a0ba8151f6081f3

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpropanes. These are organic compounds containing a phenylpropane moiety.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenylpropanes
Direct Parent
Phenylpropanes
Alternative Parents
m-Xylenes / Imidolactams / Imidazolines / Propargyl-type 1,3-dipolar organic compounds / Carboximidamides / Carboxamidines / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Phenylpropane / M-xylene / Xylene / Imidolactam / 2-imidazoline / Amidine / Carboxylic acid amidine / Azacycle / Organoheterocyclic compound / Organic 1,3-dipolar compound
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
alkylbenzene (CHEBI:10082)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Yang HT, Endoh M: (+/-)-tamsulosin, an alpha 1A-adrenoceptor antagonist, inhibits the positive inotropic effect but not the accumulation of inositol phosphates in rabbit heart. Eur J Pharmacol. 1996 Oct 3;312(3):281-91. [PubMed:8894610]
  2. Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi: 10.1111/j.1472-8206.2009.00805.x. [PubMed:20030735]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi: 10.1111/j.1472-8206.2009.00805.x. [PubMed:20030735]
  2. Petrusewicz J, Kaliszan R: Effect of imidazoline drugs on human blood platelet aggregation. Thromb Haemost. 1985 Dec 17;54(4):784-7. [PubMed:2868542]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Epinephrine binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine...
Gene Name
ADRA2B
Uniprot ID
P18089
Uniprot Name
Alpha-2B adrenergic receptor
Molecular Weight
49565.8 Da
References
  1. Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi: 10.1111/j.1472-8206.2009.00805.x. [PubMed:20030735]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi: 10.1111/j.1472-8206.2009.00805.x. [PubMed:20030735]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Alpha1-adrenergic receptor activity
Specific Function
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name
ADRA1D
Uniprot ID
P25100
Uniprot Name
Alpha-1D adrenergic receptor
Molecular Weight
60462.205 Da
References
  1. Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi: 10.1111/j.1472-8206.2009.00805.x. [PubMed:20030735]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Protein homodimerization activity
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name
ADRA2C
Uniprot ID
P18825
Uniprot Name
Alpha-2C adrenergic receptor
Molecular Weight
49521.585 Da
References
  1. Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi: 10.1111/j.1472-8206.2009.00805.x. [PubMed:20030735]

Drug created on April 25, 2010 17:54 / Updated on June 21, 2018 00:02